Tert-butyl 3,6-diazabicyclo[3.2.2]nonane-3-carboxylate | 194032-39-8

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: Tert-butyl 3,6-diazabicyclo[3.2.2]nonane-3-carboxylate
• CAS: 194032-39-8
• 化学式: C₁₂H₂₂N₂O₂
• 分子量: 226.32
• InChiKey: IHTTXKKKRHFNJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• ISOQUINOLINE DERIVATIVES AND DRUGS
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0885888A1

  公开（公告）日：1998-12-23

  The invention relates to a compound of the following general formula [I] or a medicinally acceptable salt thereof, or a solvate thereof, wherein R1 represents alkyl, alkenyl, alkynyl, alkoxy, hydroxy, cyano, or halogen; R2 represents hydrogen, hydroxy, or halogen; R3 represents hydrogen, alkyl, or amidino; Ring A represents a 5 to 11-membered cyclic amino group which may be substituted, which cyclic amino group may be bridged between two carbon atoms in optional positions. The compound of this invention is useful for the prevention or treatment of cerebral tissue impairment due to the vasospasm following cerebral hemorrhage.

  本发明涉及下式通式[I]的化合物或其药用盐或其溶液、 其中 R1 代表烷基、烯基、炔基、烷氧基、羟基、氰基或卤素；R2 代表氢、羟基或卤素；R3 代表氢、烷基或脒基；环 A 代表可被取代的 5 至 11 元环氨基，该环氨基可在任选位置的两个碳原子之间桥接。 本发明的化合物可用于预防或治疗脑出血后血管痉挛引起的脑组织损伤。
• Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US11208422B2

  公开（公告）日：2021-12-28

  The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle.

  本申请涉及新型咪唑吡啶基或咪唑嘧啶基取代的、桥接的式(I)1,4-二氮杂环庚烷衍生物，涉及其制备工艺，涉及其单独使用或组合使用以治疗和/或预防疾病，涉及其用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防呼吸系统疾病，包括与睡眠有关的呼吸系统疾病，如阻塞性睡眠呼吸暂停和中枢性睡眠呼吸暂停以及打鼾。式（I）中，环 Q 代表桥接的 1，4-二氮杂环。
• SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20200140461A1

  公开（公告）日：2020-05-07

  The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle
• US6153608A
  申请人：——

  公开号：US6153608A

  公开（公告）日：2000-11-28
• [EN] BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS CIBLANT BRM ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2021067606A1

  公开（公告）日：2021-04-08

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.